Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004070
Status:
COMPLETED
Last Update Posted:
2017-04-20
First Post:
1999-12-10
Brief Title:
Gene Therapy in Treating Patients With Unresectable Recurrent or Refractory Head and Neck Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Multi-Center Open-Label Multiple Administration Rising Dose Study of the Safety Tolerability and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or RecurrentRefractory Squamous Cell Carcinoma of the Head and Neck SCCHN
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participant with squamous cell cancer of head and neck are invited to participate in this study In this study the investigators will be Inserting the gene for interleukin-12 into a persons cancer cells with the anticipation to make the body build an immune response to kill more tumor cells
Detailed Description:
This is a Phase III trial to study the effectiveness of gene therapy in treating patients who have unresectable recurrent or refractory head and neck cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA006516 | NIH | None | None |
| VALENTIS-DFCI-99081 | None | None | None |
| NCI-G99-1578 | None | None | None |
| CDR0000067274 | OTHER | Other | httpsreporternihgovquickSearchP30CA006516 |